Compounds > gefitinib
Page last updated: 2024-09-03

gefitinib and u 0126

gefitinib has been researched along with u 0126 in 11 studies

Compound Research Comparison

Studies
(gefitinib)		Trials
(gefitinib)		Recent Studies (post-2010)
(gefitinib)		Studies
(u 0126)		Trials
(u 0126)		Recent Studies (post-2010) (u 0126)
5,2315662,9192,81621,213

Protein Interaction Comparison

ProteinTaxonomygefitinib (IC50)u 0126 (IC50)
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)0.29
Serine/threonine-protein kinase B-rafHomo sapiens (human)0.25
Amine oxidase [flavin-containing] BRattus norvegicus (Norway rat)0.07
Dual specificity mitogen-activated protein kinase kinase 2Homo sapiens (human)0.2816
Dual specificity mitogen-activated protein kinase kinase 1Homo sapiens (human)0.2529

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (27.27)29.6817
2010's6 (54.55)24.3611
2020's2 (18.18)2.80

Authors

AuthorsStudies
Bullock, AN; Fedorov, O; Knapp, S; Marsden, B; Müller, S; Pogacic, V; Rellos, P; Schwaller, J; Sundström, M1
Al-Mazaideh, GM; Erdmann, F; Göllner, C; Rohe, A; Schmidt, M; Sippl, W; Wichapong, K1
Cao, HQ; Chu, MJ; Li, QS; Liu, DH; Lv, XH; Mo, K; Ren, ZL; Yao, XK; Zhang, LS; Zhou, BG1
Bharate, SB; Raghuvanshi, R1
Caballero, E; García-Cárceles, J; Gil, C; Martínez, A1
Chayama, K; Kuwahara, K; Miyata, H; Sasaki, T; Serikawa, M1
Chen, RS; Cheng, CM; Chuang, SM; Ciou, SC; Jhan, JY; Ko, JC; Lee, WT; Lin, ST; Lin, YW; Su, YJ1
Chan, R; Jacks, T; Jasper, PJ; Lane, K; Lauffenburger, DA; Lazzara, MJ; Neel, BG; Sorger, PK; Yaffe, MB1
Banerjee, R; Belinsky, G; Huang, Y; Jean-Claude, BJ; McNamee, JP; Qiu, Q1
Grandal, MV; Grøvdal, LM; Holst, MR; Kim, J; Knudsen, SL; van Deurs, B1
Li, H; Schmid-Bindert, G; Su, B; Wang, D; Yang, X; Zhao, Y; Zhou, C1

Reviews

1 review(s) available for gefitinib and u 0126

ArticleYear
Kinase Inhibitors as Underexplored Antiviral Agents.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Animals; Antiviral Agents; Drug Repositioning; Humans; Protein Kinase Inhibitors; Virus Diseases; Viruses

2022

Other Studies

10 other study(ies) available for gefitinib and u 0126

ArticleYear
A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
    Proceedings of the National Academy of Sciences of the United States of America, 2007, Dec-18, Volume: 104, Issue:51

    Topics: Amino Acid Sequence; Binding Sites; Clinical Trials as Topic; Drug Evaluation, Preclinical; Enzyme Stability; Humans; Molecular Sequence Data; Phylogeny; Protein Array Analysis; Protein Conformation; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases

2007
Evaluation of potential Myt1 kinase inhibitors by TR-FRET based binding assay.
    European journal of medicinal chemistry, 2013, Volume: 61

    Topics: Dose-Response Relationship, Drug; Fluorescence Resonance Energy Transfer; Glycolipids; Humans; Membrane Proteins; Models, Molecular; Molecular Structure; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Protein-Tyrosine Kinases; Structure-Activity Relationship

2013
Discovery of N-(benzyloxy)-1,3-diphenyl-1H-pyrazole-4-carboxamide derivatives as potential antiproliferative agents by inhibiting MEK.
    Bioorganic & medicinal chemistry, 2016, 10-01, Volume: 24, Issue:19

    Topics: Antineoplastic Agents; Biphenyl Compounds; Cell Line, Tumor; Cell Proliferation; Humans; MAP Kinase Kinase 1; MAP Kinase Signaling System; Molecular Docking Simulation; Neoplasms; Protein Kinase Inhibitors; Pyrazoles; Quantitative Structure-Activity Relationship

2016
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022
The effects of ZD1839 (Iressa), a highly selective EGFR tyrosine kinase inhibitor, as a radiosensitiser in bile duct carcinoma cell lines.
    International journal of oncology, 2006, Volume: 28, Issue:4

    Topics: Anthracenes; Bile Duct Neoplasms; Butadienes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Chromones; Clone Cells; Dose-Response Relationship, Drug; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Gefitinib; Humans; Imidazoles; JNK Mitogen-Activated Protein Kinases; Mitogen-Activated Protein Kinases; Morpholines; Nitriles; Oncogene Protein v-akt; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Protein Kinase Inhibitors; Pyridines; Quinazolines; Radiation-Sensitizing Agents

2006
Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation.
    Experimental cell research, 2009, Sep-10, Volume: 315, Issue:15

    Topics: Animals; Antineoplastic Agents; Apoptosis; Butadienes; Cell Line, Tumor; Emodin; Gefitinib; Humans; MAP Kinase Kinase 1; Mitogen-Activated Protein Kinase 1; Mitogen-Activated Protein Kinase 3; Nitriles; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Quinazolines; Rad51 Recombinase; RNA, Small Interfering; Signal Transduction

2009
Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations.
    Cancer research, 2010, May-01, Volume: 70, Issue:9

    Topics: Animals; Antineoplastic Agents; Butadienes; Carcinoma, Non-Small-Cell Lung; Enzyme Activation; Enzyme Inhibitors; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; HeLa Cells; Humans; Lung Neoplasms; Mice; Mutation; Nitriles; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 11; Quinazolines

2010
The combi-targeting concept: mechanism of action of the pleiotropic combi-molecule RB24 and discovery of a novel cell signaling-based combination principle.
    Cellular signalling, 2011, Volume: 23, Issue:4

    Topics: Antineoplastic Agents; Apoptosis; Butadienes; Cell Line, Tumor; Cell Proliferation; Cell Survival; Dacarbazine; DNA Damage; DNA Methylation; Drug Synergism; Enzyme Activation; ErbB Receptors; Gefitinib; Humans; Inhibitor of Apoptosis Proteins; Intracellular Signaling Peptides and Proteins; Mitogen-Activated Protein Kinases; Nitriles; Phosphorylation; Quinazolines; Signal Transduction; Temozolomide; Triazenes

2011
EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
    Cellular signalling, 2012, Volume: 24, Issue:1

    Topics: Breast Neoplasms; Butadienes; Cell Line, Tumor; Chromones; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Gene Expression; Gene Expression Profiling; Humans; Imidazoles; MAP Kinase Kinase 1; Morpholines; Nitriles; p38 Mitogen-Activated Protein Kinases; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphorylation; Proto-Oncogene Proteins c-akt; Pyridines; Quinazolines; Receptor, ErbB-2; Receptor, ErbB-3; Receptor, ErbB-4; RNA, Messenger; Signal Transduction; Tyrphostins; Up-Regulation

2012
Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
    Advances in medical sciences, 2011, Volume: 56, Issue:2

    Topics: Antineoplastic Agents; Apoptosis; Butadienes; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Chromones; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Flow Cytometry; Gefitinib; Humans; Lung Neoplasms; MAP Kinase Kinase Kinases; Morpholines; Mutation; Nitriles; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction

2011